SCHEMBL15935018

SCHEMBL15935018

COc1nccc(-n2ccc(C)n2)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.54
RAB9A P51151 3/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
NPC1 O15118 2/20 0.54
ATM Q13315 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
KDM4E B2RXH2 3/20 0.38
ALDH1A1 P00352 2/20 0.38
GAA P10253 1/20 0.38
ROCK1 Q13464 2/20 0.33
TDO2 P48775 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
HTT P42858 1/20 0.33
MAPK13 O15264 1/20 0.32
MAPK12 P53778 1/20 0.32
MAPK11 Q15759 1/20 0.32
MAPK14 Q16539 1/20 0.32
CYP1A2 P05177 2/20 0.32
CYP3A4 P08684 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23175861 0.83 MAPK13 (0.41) MAPTRAB9ASMN1; SMN2NPC1ATM
SCHEMBL15923550 0.83 MAPT (0.34) MAPTRAB9ASMN1; SMN2NPC1ATM
SCHEMBL19132921 0.80 KDM5A (0.40) MAPTRAB9ASMN1; SMN2NPC1ATM
SCHEMBL15935396 0.80 MAPT (0.61) MAPTRAB9ASMN1; SMN2NPC1ATM
SCHEMBL27129458 0.77 MAPT (0.46) MAPTRAB9ASMN1; SMN2NPC1ATM
SCHEMBL19100786 0.77 MAPT (0.58) MAPTRAB9ASMN1; SMN2NPC1ATM
SCHEMBL15935402 0.75 MAPT (0.56) MAPTRAB9ASMN1; SMN2NPC1ATM
SCHEMBL19132920 0.75 KDM4E (0.44) MAPTRAB9ASMN1; SMN2NPC1KDM4E
SCHEMBL23176145 0.74 PDPK1 (0.36) MAPTRAB9ASMN1; SMN2NPC1ROCK1
SCHEMBL15935022 0.74 BRD4 (0.34) KDM4EMAPK13MAPK12MAPK11MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2934538-B1 FACTOR IXA INHIBITORS MERCK SHARP & DOHME (US) 2021-03-31 EP disclosed
US-9708308-B2 Factor IXa inhibitors MERCK SHARP DOHME CORP. (US) 2017-07-18 US disclosed
US-20150322056-A1 Factor IXa Inhibitors MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2015-11-12 US disclosed
WO-2014120346-A1 FACTOR IXA INHIBITORS MERCK SHARP & DOHME CORP. (US) 2014-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150322056-A1 Factor IXa Inhibitors F9, F12, F8 MAPT 4751/4885RAB9A 556/4885SMN1; SMN2 2530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.